As one example, imatinib, the first major drug in its class of specific inhibitors of tyrosine kinase receptors, has been found to be far less effective in patients who relapsed with accelerated and blast phases of CML [1]. This evidence concerns the gene NTRK1 and chronic myelogenous leukemia, BCR-ABL1 positive.